MICROWAVE ABLATION
FOR THYROID NODULES
For patients with symptomatic benign thyroid nodules, microwave ablation offers a no-scar, outpatient alternative to surgery that preserves thyroid function and avoids lifelong hormone replacement. The procedure has become a leading option at experienced centres globally.
analyticsAt a Glance
- check_circleEstablished option for symptomatic benign thyroid nodules
- check_circleOutpatient procedure under ultrasound guidance and local anaesthesia
- check_circleAverage nodule volume reduction 50โ80% at 6โ12 months
- check_circlePreserves thyroid function โ no lifelong hormone replacement needed
The Thyroid Nodule Problem and Why Ablation Matters
Thyroid nodules are extremely common โ found on ultrasound in 30โ50% of adults. The vast majority are benign and asymptomatic. But a meaningful subset cause real problems: nodules that compress the trachea or oesophagus, cause cosmetic distress through visible neck swelling, or autonomously produce thyroid hormone causing hyperthyroidism. For these patients, the historical options were continued observation or surgical removal. Microwave ablation has changed that.
โThyroid surgery means hospitalisation, general anaesthesia, a permanent neck scar, potential nerve injury, and โ if both lobes are removed โ lifelong thyroid hormone replacement. MWA delivers tumour treatment without these costs.โ
No Visible Scar
Thyroid surgery leaves a 4โ8 cm scar across the front of the neck โ typically visible and a major concern for many patients, particularly those who wear shirts open at the collar or work in client-facing roles. MWA leaves only a single needle entry point that heals within days.
Preserves Thyroid Function
Surgical removal of one or both thyroid lobes often results in hypothyroidism requiring lifelong levothyroxine replacement. MWA destroys only the targeted nodule, preserving surrounding healthy thyroid tissue. Most patients maintain normal thyroid function and need no hormone replacement.
When MWA Is Used for Thyroid Nodules
MWA fits into thyroid nodule management at specific clinical scenarios. The strongest evidence base is for symptomatic benign nodules; emerging evidence supports its use in low-risk thyroid cancer at specialised centres.
Symptomatic Benign Nodules (Strongest Indication)
Nodules causing compression symptoms โ difficulty swallowing, sensation of pressure, breathlessness when lying flat, or visible neck swelling causing cosmetic distress. Biopsy must confirm benign cytology (Bethesda category II) before ablation. This is the most established MWA indication globally.
Autonomously Functioning ("Hot") Thyroid Nodules
Nodules producing thyroid hormone independent of TSH regulation, causing hyperthyroidism or subclinical hyperthyroidism. MWA can destroy the autonomous tissue, restoring normal thyroid function. Alternatives include radioactive iodine and surgery; MWA offers faster onset of effect than radioiodine.
Recurrent Benign Nodules after Prior Surgery
Patients who previously had thyroid surgery and developed new benign nodules requiring treatment. Re-operation carries higher risk of nerve injury due to scar tissue. MWA provides effective treatment with substantially lower risk in this setting.
Low-Risk Papillary Thyroid Microcarcinoma (Emerging Indication)
For small (<1 cm) low-risk papillary thyroid carcinomas in selected patients, MWA is being studied as an alternative to surgery or active surveillance. This indication is investigational and offered primarily at experienced specialist centres, particularly in Asia. Patient selection requires careful multi-disciplinary review.
Cervical Lymph Node Metastases from Thyroid Cancer (Selected)
For patients with limited cervical nodal metastases after thyroidectomy who are not surgical candidates for neck dissection, ablation of accessible nodes may be considered. This is a specialised application requiring experienced operators.
Patient Selection for Thyroid MWA
Selection criteria balance the procedure's benefits against the patient's specific clinical situation.
| Factor | Strong Candidate | Less Strong / Alternative Approaches |
|---|---|---|
| Nodule Cytology | Benign (Bethesda II) confirmed on biopsy | Indeterminate (Bethesda III/IV) or malignant cytology โ typically need surgery |
| Nodule Size | 2โ5 cm โ best outcomes | Very large (>6 cm) โ may need multiple sessions or surgery |
| Nodule Composition | Mostly solid (>50% solid component) | Predominantly cystic โ ethanol ablation may be preferred |
| Symptoms | Compressive symptoms, cosmetic concerns, hyperthyroidism | Asymptomatic benign nodule โ observation usually preferable |
| Anatomical Considerations | Safe distance from recurrent laryngeal nerve, trachea, oesophagus | Nodule extending behind sternum or surrounding vital structures |
| Patient Health Status | Suitable for outpatient procedure under local anaesthesia | Severe coagulopathy or bleeding disorders |
| Number of Symptomatic Nodules | One or few dominant nodules | Diffuse multinodular goitre with diffuse symptoms โ surgery may be preferable |
Thyroid MWA vs Thyroid Surgery
Direct comparison of the two treatment paths for symptomatic thyroid nodules.
MWA Advantages
- No Visible ScarSingle needle entry point heals within days; no permanent neck scar.
- Outpatient ProcedurePerformed under local anaesthesia; patient typically goes home within 1โ2 hours.
- Preserves Thyroid FunctionHealthy thyroid tissue retained; most patients avoid hormone replacement.
- Lower Procedural RiskSubstantially lower risk of recurrent laryngeal nerve injury, hypocalcaemia, and surgical complications.
- Faster RecoveryMost patients return to work within 1โ3 days vs 1โ2 weeks for surgery.
- RepeatableCan be repeated if nodule regrows or new nodules develop.
Surgery Advantages
- Definitive Tissue DiagnosisSurgical pathology provides complete histological assessment including for occult malignancy.
- Better for Very Large NodulesNodules >6 cm or extending behind sternum often need surgical removal.
- Standard for Malignant DiseaseConfirmed thyroid cancer (except selected low-risk microcarcinomas) is treated surgically; ablation is generally not curative-intent for most malignancies.
- Established Long-Term OutcomesDecades of long-term follow-up data; MWA has shorter follow-up history.
- Complete RemovalSurgery removes the entire nodule and lobe; MWA achieves volume reduction but small residual treated tissue remains.
Outcomes Data: Thyroid Nodule Ablation
Published outcomes from major series of MWA for benign thyroid nodules.
Volume Reduction at 6โ12 Months โ Benign Thyroid Nodules
Average nodule volume reduction from baseline at major time points.
- At 3 Months40โ55%
- At 6 Months55โ75%
- At 12 Months60โ85%
- At 24 Months65โ90%
Symptom Improvement Rates
Proportion of patients reporting symptom relief at 6 months post-procedure.
- Compressive Symptoms โ Improvement85โ95%
- Cosmetic Score Improvement85โ92%
- Hyperthyroidism Resolution60โ80%
Complication Rates
Procedural complications from major thyroid MWA series.
- Mild Pain / Discomfort10โ20%
- Transient Voice Change1โ3%
- Permanent Recurrent Laryngeal Nerve Injury<1%
- Major Bleeding / Haematoma<1%
The Thyroid MWA Procedure
A typical thyroid MWA procedure from preparation through follow-up.
- 1
Step 1: Pre-Procedure Evaluation
Ultrasound of the nodule, fine-needle aspiration biopsy confirming benign cytology, thyroid function tests (TSH, T4, T3), and assessment of nodule location relative to nerves and major vessels. Patient counselling on expectations and recovery.
- 2
Step 2: Patient Positioning and Local Anaesthesia
Patient lies supine with neck slightly extended. The skin over the nodule is cleaned and infiltrated with local anaesthetic. Many centres use lidocaine plus mild oral sedation; general anaesthesia is rarely needed.
- 3
Step 3: Ultrasound-Guided Antenna Placement
Real-time ultrasound guidance directs the MWA antenna into the nodule. The "trans-isthmic" approach is commonly used โ entering from the front of the neck and crossing through the isthmus to reach the nodule, allowing safe access and protection of nearby structures.
- 4
Step 4: Moving-Shot Ablation Technique
MWA energy delivered while gradually withdrawing the antenna in small steps, creating an overlapping series of ablation zones throughout the nodule. The "moving-shot" technique allows controlled coverage with minimal risk to surrounding structures.
- 5
Step 5: Post-Procedure Assessment
Immediate post-ablation ultrasound assesses ablation coverage. Brief observation period (1โ2 hours) monitors for complications. Most patients discharged the same day with simple instructions for activity and pain management.
- 6
Step 6: Follow-Up Assessment
Ultrasound at 1, 3, 6, 12, and 24 months tracks volume reduction. Thyroid function monitored. New symptoms or growth prompt additional evaluation. Many patients see continued nodule shrinkage for 12โ24 months after the procedure.
Related Treatments & Resources
Explore the full microwave ablation knowledge base.
Frequently Asked Questions
Common questions about microwave ablation for thyroid nodules.
About the Treatment
Is MWA safe for thyroid nodules near the voice box nerves?
Yes, when performed by experienced operators. The recurrent laryngeal nerves run very close to the thyroid and can be injured during surgery or ablation. Experienced operators use specific techniques โ careful ultrasound monitoring, the moving-shot approach, hydrodissection with saline injection to push nerves away from the ablation zone โ to minimise risk. Permanent nerve injury rates are <1% at experienced centres, lower than surgical rates.
Will the nodule come back after MWA?
Some volume regrowth can occur in 5โ15% of patients, particularly for very large nodules or those with significant cystic components. Re-treatment with repeat MWA is straightforward when regrowth occurs. The majority of patients maintain durable volume reduction for years after the procedure.
Do I need to take thyroid hormone after MWA?
Generally not. Because MWA preserves surrounding healthy thyroid tissue, most patients maintain normal thyroid function and do not need hormone replacement. About 5โ10% may develop transient or mild persistent hypothyroidism that resolves or requires only low-dose supplementation. This contrasts with surgery, where bilateral lobectomy uniformly requires lifelong hormone replacement.
About Outcomes and Eligibility
Can MWA be used for thyroid cancer?
For most thyroid cancers โ papillary, follicular, medullary, anaplastic โ surgical resection remains the standard of care with the strongest evidence base. MWA is being studied as an alternative for selected low-risk papillary thyroid microcarcinomas (<1 cm, no spread, no aggressive features) at experienced centres, particularly in Asia. This indication remains investigational and is not yet standard practice globally.
How long until I see results?
Volume reduction is gradual. Most patients see noticeable shrinkage at 3 months, substantial reduction by 6 months, and maximum effect by 12โ24 months. Compressive symptoms typically improve within weeks of the procedure. Cosmetic improvement is visible by 3โ6 months. Patience is required โ this is not an instant result.
How does CancerFax help me access thyroid MWA?
CancerFax reviews your ultrasound images, biopsy results, and thyroid function tests to assess MWA candidacy. We coordinate review with experienced interventional endocrine centres globally โ including major Korean, Chinese, Italian, and US programmes that have developed extensive thyroid MWA experience. We provide transparent cost estimates and travel logistics for international patients.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Considering MWA for a Thyroid Nodule?
Upload your medical records โ ultrasound imaging, biopsy results, thyroid function tests, and your symptom history. Our interventional endocrine team will review your case to assess MWA candidacy and identify experienced centres.
This content is for informational purposes only. Thyroid nodule treatment decisions require evaluation by qualified endocrine and interventional specialists. Confirm benign cytology before considering ablation.